Centene (CNC) Q2 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2026 earnings summary
28 Jul, 2026Executive summary
Q2 2026 adjusted diluted EPS was $2.51, exceeding expectations and reflecting strong profitability improvements year-over-year, with GAAP diluted EPS at $2.19.
Total revenues for Q2 2026 reached $53.6 billion, up 10% year-over-year, driven by premium tax revenue, PDP growth, and rate increases in Marketplace and Medicaid.
Managed care membership declined 8% year-over-year to 25.9 million, primarily due to Medicaid redeterminations and regulatory changes.
Margin restoration, operational transformation, and ongoing investments in AI, data, and organizational optimization remain key priorities.
Cash flow from operations for Q2 2026 was $3.6 billion, primarily from net earnings and payment timing.
Financial highlights
Premium and service revenues increased 4% year-over-year to $44.4 billion in Q2 2026.
Health benefits ratio (HBR) improved to 89.6% from 93.0% in Q2 2025, reflecting improved pricing and risk transfer.
Adjusted SG&A expense ratio improved to 6.9% from 7.1% year-over-year.
Net earnings attributable to shareholders were $1.1 billion for Q2 2026, up from a loss of $253 million in Q2 2025.
Operating income rose to $1.2 billion from a loss of $458 million year-over-year.
Outlook and guidance
2026 adjusted diluted EPS guidance raised to greater than $4.80, and GAAP diluted EPS guidance raised to greater than $3.11.
Total revenues guidance for 2026 increased to $193.5–$197.5 billion; premium and service revenues guidance raised to $173.0–$177.0 billion.
Marketplace pre-tax margin guidance raised to 4.5%-5% for 2026; PDP pre-tax margin expected to be greater than 3%.
Medicaid HBR forecast remains at 93.5% for the full year, with membership expected to decline 8%-9% from 12/31/2025.
Projected severance costs of $315–$365 million in 2026 related to enterprise optimization initiatives.
Latest events from Centene
- Q2 2025 saw higher revenues but a net loss from medical costs and Marketplace risk adjustment shortfall.CNC
Q2 20259 Jul 2026 - 2025 EPS guidance exceeds $7.25, with premium/service revenue at $154–$156B and growth in Duals and ICHRA.CNC
Investor Day 20248 Jul 2026 - 2024 EPS rose 7% to $7.17; 2025 revenue guidance increased by $4B to $158–$160B.CNC
Q4 20248 Jul 2026 - 2026 guidance targets adjusted EPS above $3.00, with margin recovery and debt reduction focus.CNC
Q4 20258 Jul 2026 - Q1 2025 adjusted EPS up 28% to $2.90, revenue up 17% to $46.6B, guidance raised.CNC
Q1 20251 Jul 2026 - Q1 2026 EPS and revenues exceeded expectations, with improved leverage and strong segment results.CNC
Q1 202628 Apr 2026 - Operational disruption in 2025 drives strategic refocus, governance refresh, and margin recovery plans.CNC
Proxy filing26 Mar 2026 - Key votes include director elections, executive pay, auditor ratification, and board chair proposal.CNC
Proxy filing26 Mar 2026 - 2026 EPS guidance reaffirmed; core businesses on track, with focus on fraud prevention and risk adjustment.CNC
Barclays 28th Annual Global Healthcare Conference10 Mar 2026